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INTRODUCTION 
 
Rheumatoid arthritis is a chronic immune-inflammatory systemic 
disease which affects synovial joints with possibility of extraarticular 
manifestations1. 
Rheumatoid arthritis prevalence is approximately 0.8% (0.3 to 
2.1%) of population worldwide2. Our Indian data suggest prevalence to 
be around 0.65 to 0.75%. 
 Rheumatoid arthritis is primarily a joint disease, but extraarticular 
manifestation can be detected in any organ system and may occasional 
precede the onset of arthritis. Most common neurological manifestation in 
rheumatoid arthritis is entrapment neuropathy  which is secondary to 
proliferative synovitis3. 
About  33.2% of the patients develop neurological problems during 
their lifetime3.Peripheral nerve involvement in rheumatoid arthritis  
includes compressive neuropathy, which is by far the commonest , distal 
sensory and combined sensorimotor neuropathy4.  
 Although the underlying pathology resulting in rheumatoid 
neuropathy is not clear, ischemia secondary to vasculitis with 
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characteristic axonal loss and humoral mechanisms such as the deposition 
of immune complexes and fixation of complement are thought to be 
important factors5. The arteritis of small vessels commonly fibrinoid type 
and immune globins are demonstrated in walls of the vessels6. 
The presence of peripheral neuropathy in patients with rheumatoid 
arthritis is difficult to recognize as patients often related  neurological 
symptoms to joint disease. It is also difficult to assess neurological 
system in the presence of severe joint disease5. Hence our current study is 
undertaken to evaluate the prevalence and pattern of neuropathy in 
rheumatoid arthritis and to correlate it with disease parameter and other 
extraarticular involvement. 
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AIMS AND OBJECTIVES 
1. To study the prevalence of peripheral neuropathy in Rheumatoid 
arthritis. 
2. To know the pattern of neuropathy in Rheumatoid arthritis. 
3. To correlate neuropathy with disease parameters and other extra 
articular involvement. 
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REVIEW OF LITERATURE 
 Rheumatoid arthritis a chronic inflammatory multisystem disease 
of unknown etiology with characteristic features of persistant 
inflammatory synovitis affecting mostly peripheral joints symmetrically. 
This inflammation leads on to cartilage destruction, bony erosions and 
presenting finally as joint deformity. 
The main manifestations involve the joints, studies done before 
have reported that extra-articular manifestations occur in 10%–20%of RA 
patients. These  symptoms correlate with increased mortality. Clinical 
neuropathy occurs in 0.5% to 85% of RA patients. They present in the 
form of mononeuritis multiplex, sensorimotor neuropathy and entrapment 
neuropathy. Clinical neuropathy may present with wide variety of 
symptoms like pain, paresthesias, and muscle weakness. These symptoms 
mimic and overlap those of arthritis, and  hence difficult to distinguish 
peripheral neuropathy symptoms from arthritis symptoms. 
Clinical research over two decades have revolutionized the 
contemporary paradigms for diagnosis and treatment of Rheumatoid 
arthritis. Serum antibodies to Cyclic Citrulinated peptides is used 
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routinely along with rheumatoid factor for diagnostic and prognostic 
significance. 
Newer imaging techniques improved our ability to detect joint 
inflammation and destruction in Rheumatoid arthritis. Incomplete 
understanding of initial pathogenic pathways remains seizable barriers to 
prevent and cure Rheumatoid arthritis. The description of crippling 
arthritis encountered less frequently due to therapeutic armamentarium 
plus adopting early treatment intervention leading to remarkable 
improvement in outcome of  Rheumatoid arthritis. Early identification of 
problem and referring patients with inflammatory arthritis to 
rheumatologist for correct diagnosis and initiating treatment is of clinical 
significance. 
Clinical presentation of rheumatoid arthritis starts increasing 
between 25 to 55 years of age, plateaus until 75 years of age and then 
decreases. Symptoms of rheumatoid arthritis results from inflammation of 
joints , tendon and bursae. Early morning stiffness of more than 1 hr 
which reduces with physical activity. Most common and early 
involvement seen in small joints of hand and feet. Pattern of joint 
involvements are monoarticular, oligoarticular (<4) joints, polyarticular 
(>5) joints  usually in symmetric distribution. 
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Some inflammatory arthritis effects very few  joints classified 
initially as undifferentiated Inflammatory arthritis later diagnosed to be 
rheumatoid arthritis having more joint involvement and having positive 
serum Rheumatoid Factor or  Anti-CCP antibodies. They also show high 
scores for physical disability. Wrist joint, metacarpophalangeal joints, 
proximal interphalangeal joints are most frequently involved. Distal 
interphalangeal joints may be involved in rheumatoid arthritis but usually 
co-exist with osteoarthritis. Hallmark of Rheumatoid arthritis is flexor 
tendon tenosynovitis. 
  
 
7 
 
FLEXOR TENOSYNOVITIS 
This leads  to reduced range of movements ,reduced grip strength 
and trigger fingers. Destruction of joints and soft tissues  progressively 
leads to chronic irreversible deformities. Subluxation of  
metacarpophalangeal  joints with subluxation of proximal phalanx to 
volar side results in Ulnar deviation. Some of the deformities commonly 
seen in rheumatoid arthritis are, 
“Swan Neck deformity” –hyperextension of proximal inter 
phalangeal joint with flexion of distal inter phalangeal joint. 
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SWAN NECK DEFORMITY 
“Boutonniere deformity”  - flexion of proximal inter phalangeal 
joint with hyperextension of Distal inter phalangeal joint 
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BOUTONNIERE DEFORMITY 
“ Z-LINE deformity ” – subluxation of first meta carpo phalangeal  
joint with hyper extension of first inter phalangeal joint. 
 
Z-LINE DEFORMITY 
In feet early feature of disease is metatarsophalangeal joint 
involvement. Inflammation of ankle and midtarsal  regions chronically 
leads on to pesplanovalgus- Flat feet.  Large joints like knee and shoulder 
joints affected in established disease and they remain asymptomatic for 
many years after onset. Cervical spine involvement is noteworthy as it is 
potential to cause  compressive myelopathy and neurological dysfunction. 
Atlantoaxial involvement of cervical spine presents with signs and 
symptoms of  neurological dysfunction with progressive instability of C1 
on C2. 
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EXTRAARTICULAR  MANIFESTATIONS: 
Extraarticular manifestations develop during clinical course of 
rheumatoid arthritis7. Patients with history of smoking develop 
extraarticular disease, early onset of significant disability and usually 
positive for serum Rheumatoid factor. Most frequently observed 
extraarticular manifestations are rheumatoid nodules ,secondary sjogren’s  
syndrome, pulmonary nodules, cardiac manifestations ,haematological  
features ,vasculitis, neurological manifestations,osteoporosis , lymphoma 
and others. 
SYSTEMIC SYMPTOMS: 
Systemic features like fever, weight loss, fatigue, malaise, in  
severe cases cachexia. This reflects higher degree of inflammation.  
Subcutaneous nodules seen in 30 to 40 % of patients. Typically  
benign may be associated with infection. Usually seen in height of 
disease activity with positive rheumatoid factor and x-ray evidence of 
joint erosions.  
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RHEUMATOID NODULES: 
 
Nodules  are firm, non tender, adherent to periostium, bursae or 
tendons. Occurs in the areas of repeated trauma or irritation such as 
forearm, achilles tendon and sacral prominences. Nodules sometimes 
seen in lungs, pleura, pericardium and peritoneum . 
HEMATOLOGICAL 
Patients  often develops normocytic, normochromic anemia. It’s 
the most frequent hematological  abnormality. Anemia may not be that 
much evident clinically. Anemia usually correlates with the degree of 
inflammation, levels of c- reactive protein and ESR value. Platelet counts 
are elevated as an acute phase reactant.  
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 In some patients, triad of neutropenia, rheumatoid nodules and 
splenomegaly is seen defined as Felty’s syndrome. Typically occurs in 
white patients in late stage of severe disease and its incidence is 
decreasing due to aggressive treatment. Leukopenia may be seen but is 
most often due to drug treatment. Lymphomas are seen quiet commonly 
in patients with rheumatoid arthritis. Common type seen 
histopathologicaly  is diffuse large B-cell lymphoma . Its incidence 
usually coorelates with disease activity. 
PULMONARY  MANIFESTATIONS : 
Pulmonary manifestations like pleuritic chest pain ,dyspnea , 
pleural friction rub and pleural effusion are usually seen. Pleural effusion 
is usually exudative. Pulmonary nodules seen may be solitary or multiple. 
Interstitial lung disease may also occur, presenting with progressive 
dyspnea and dry cough. Pulmonary function test shows restrictive pattern. 
Diagnosis made by high resolution chest computer tomography. 
 ILD confers poor prognosis but responds favourably to 
immunosuppressive treatment than idiopathic ILD. 
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CARDIAC MANIFESTATIONS 
 Pericardium is the most frequent site of cardiac involvement. 
Pericarditis occur in less than 10% of patients with rheumatoid arthritis. 
Cardiomyopathy is another manifestation of rheumatoid arthritis. Heart 
muscle may contain rheumatoid nodules. Mitral regurgitation is the most 
common abnormality in rheumatoid arthritis. 
VASCULITIS  
Rheumatoid vasculitis seen most commonly in long standing case 
with positive serum rheumatoid factor and hypocomplementemia. 
Cutaneous signs include petechiae, purpura, digital infarcts, 
livedoreticularis, painful lower limb ulceration. Vasculitic ulcers treated  
successfully with immuno suppressants  and  skin grafting. Sensorimotor 
polyneuropathies like mononeuritis multiplex occur in association with 
rheumatoid vasculitis. 
NEUROLOGICAL  
Neuropathy occurs in 0.5% to 85% of rheumatoid arthritis patients. 
Clinically presents in the form of mononeuritis multiplex, sensory motor 
neuropathy and entrapment neuropathy. These patients presents with 
varied symptomatology like pain ,paresthesiaand muscle weakness. These 
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symptoms mimic and overlap with those of arthritis. Its difficult to 
distinguish arthritis symptoms from neuropathic symptoms. Entrapment 
neuropathies occur secondary to proliferative synovitis or joint 
deformities and commonly involve median, ulnar, radial or anterior tibial 
nerve. 
Diagnosis of neuropathy is possible by nerve conduction study to 
show objectively the existence and distribution of subclinical 
neuropathies. They also provide quantitative and qualitative insight into 
neuromuscular function. 
Rheumatoid arthritis affects about 0.5-1%  of adult population 
globally. African and Asian population showed lower prevalence in the 
range of 0.2 – 0.4% . Rheumatoid arthritis occur commonly in females 
than males in 2-3:1 ratio.  
 Studies from Latin America and Africa  shows female to male 
ratio 6-8:1. Various theories proposed preponderance in female is due to 
estrogen in disease pathogenesis. Theories centered the role of estrogen in 
enhancing   immune response. Experimental studies shown than estrogen  
stimulate production of TNF-alpha, major cytokines in the pathogenesis 
of rheumatoid arthritis. 
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Genetic  factors  contribute  to the occurence  and severity of  
rheumatoid arthritis. First degree relatives of patient share the diagnosis  
of rheumatoid arthritis 2-10 times greater than general population . Twin 
studies showed that genetic factors explain upto 60% of occurence of 
rheumatoid arthritis. Genetic influence varies across studies due to 
environment – gene  intractions.                  
Alleles known to cause greatest risk of rheumatoid arthritis located 
within Major Histo Compatibility (MHC)- HLA –DR B1 gene encodes 
MHC II beta chain molecule shows close association in genetic risk of 
rheumatoid arthritis. 
Genomic studies have showed the possible identification of  
several non – MHC related genes in rheumatoid arthritis susceptibility. 
Non-MHC loci at risk alleles for rheumatoid arthritis has only modest 
effect on risk and also contribute to other autoimmune diseases like Type 
I Diabetes Mellitus, Systemic Lupus Erythematosus and Multiple 
Sclerosis. Non-HLA association also been described in patients with Anti 
CCP- antibodies positive disease. Risk alleles varies with ethnic groups. 
Risk  alleles identified by non – MHC loci only account approximately 
5% of genetic risk .This suggests other DNA varieties  yet to found that 
contribute to overall risk model.   
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Environmental factors have been implicated in the pathogenesis of 
RA .Most reproducible of the environmental factor is cigarette smoking. 
Various cohort and case control studies demonstrated that smoking 
confers relative risk for developing. 
 Rheumatoid arthritis of 1.5–3.5. Women who smoke cigarettes 
have nearly 2.5 times greater risk of Rheumatoid arthritis, risk that 
persists even 15 years after smoking cessation. Twin who smoke will 
have significantly higher risk for Rheumatoid arthritis than his or her 
monozygotic co-twin. Interestingly risk from smoking is almost 
exclusively related to Rheumatoid Factor and anti-CCP antibody-positive 
disease. It  been shown that smoking cessation, while having many health 
benefits, doesn’t  improves disease activity.  
Researchers began to aggressively search an infectious cause for 
Rheumatoid arthritis after discovery in 1931 that sera from patients with 
this disease could agglutinate strains of streptococci. Viruses such as 
Epstein-Barr virus (EBV) have garnered most interest over past 30 years 
given their ubiquity, ability to persist many years in the host, and frequent 
association with arthritic complaints. 
Titers of IgG antibodies against EBV antigens in the blood and 
saliva are significantly higher in patients with Rheumatoid arthritis than 
  
 
17 
general population. EBV DNA is also been found in synovial   fluids and 
cells of Rheumatoid arthritis patients. The evidence for these links is 
largely circumstantial, it has not been possible to directly implicate 
infection as  causative factor in Rheumatoid arthritis.  
Rheumatoid arthritis affects synovial tissue, underlying cartilage 
and bone. Synovial membrane, which covers most articular surfaces, 
tendon sheaths and bursae, normally is a thin layer of connective tissue. 
Synovial membrane consists primarily of two cell  types 
1: Type A  synoviocytes    (macrophage-derived) 
2: Type B synoviocytes (fibroblast-derived)  
The synovial  fibroblasts  form  the most abundant and produce 
structural components of joints, including collagen, fibronectin, laminin, 
and other extracellular constituents of synovial matrix. Pathologic  
hallmarks of Rheumatoid arthritis are synovial inflammation and 
proliferation, focal bone erosions, and thinning of articular cartilage. 
Chronic inflammation leads on to synovial lining hyperplasia and 
formation of pannus, a thickened cellular membrane contains fibroblast-
like synoviocytes and granulation-reactive fibrovascular tissue that 
invades underlying cartilage and bone. The inflammatory infiltrate is 
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made of not less than six cell types: T -cells, B- cells, plasma cells, 
dendritic cells, mast cells, and granulocytes. T-cells comprise 30–50%  of 
the infiltrates. The topographical organization of these cells is complex 
and vary among individuals  with Rheumatoid arthritis.  
Structural damage to the mineralized cartilage and subchondral 
bone is mediated by osteoclast.  Osteoclasts are multinucleated giant cells 
that are identified by the expression of CD68, tartrate resistant acid 
phosphatase, cathepsin  K, and calcitonin receptor. They appear at 
pannus-bone interface where it eventually form resorption lacunae. These 
kind of lesions typically localize where synovial membrane inserts into 
periosteal surface at the edges of bones close to the rim of articular  
cartilage and at  the attachment sites of ligaments and tendon sheaths. 
This most likely explains why bone  erosions usually develop at radial 
sites  of the MCP joints juxtaposed to insertion sites of the tendons, 
collateral ligaments and synovial membrane. Another form which leads to 
bone loss  is periarticular osteopenia that occurs in joints with active 
inflammation. In recent  years, concept of joint pathology in Rheumatoid 
arthritis has been extended to include the bone marrow cavity. 
Generalized osteoporosis, which results in the thinning of  trabecular 
bone throughout the body, it’s a third form of bone loss found in patients 
with Rheumatoid arthritis . 
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PATHOGENESIS  
Pathogenic  mechanisms of synovial inflammation are likely to 
result from complex interplay of genetic ,environmental, and 
immunologic factors that produces dysregulation of immune system and 
breakdown in self-tolerance. What triggers these initiating events and 
genetic , environmental factors that disrupt the immune system remains a 
mystery. But detailed molecular picture is emerging of the mechanisms 
underlying the chronic inflammatory response and the destruction of the 
articular cartilage and bone. 
Preclinical stage in Rheumatoid arthritis appears to be 
characterized by breakdown in self-tolerance. This is supported by the 
finding that autoantibodies, such as Rheumatoid factor and  anti-CCP 
antibodies, may be found in sera from patients many years before clinical 
disease is detected. However, the antigenic targets of anti-CCP antibodies 
and Rheumatoid factor are not restricted to joints , and their role in 
disease pathogenesis remains speculative. Anti-CCP antibodies are 
directed against deaminated peptides, that result from posttranslational 
modification by the enzyme PADI4. It recognize citrulline-containing 
regions of several different matrix proteins, including  filaggrin, keratin, 
fibrinogen and vimentin, and present at higher levels in the joint fluid 
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compared to the serum. Other autoantibodies  have been found in 
minority of patients with Rheumatoid arthritis ,but they also occur in 
other types of arthritis. People who smoke display higher citrullination of 
proteins in bronchoalveolar fluid than those who do not smoke. It has 
been speculated that long-term exposure to tobacco smoke might induce 
citrullination of cellular proteins in lung and stimulate expression of 
neoepitope capable of inducing self-reactivity, which in turn, leads to 
formation of immune complexes and joint inflammation. Exposure to 
silicone dust and mineral oil , has also been linked to an increased risk for 
anti-CCP antibody-positive Rheumatoid arthritis.  
The immune system is alerted by the presence of microbial 
infections through Toll-like  receptors (TLRs). TLR 2,-3,and -4 are 
abundantly expressed by synovial fibroblasts in early Rheumatoid 
arthritis . Specific  role for TLRs in disease pathogenesis is not been 
elucidated. Pathogenesis of Rheumatoid arthritis is built upon the concept 
that self-reactive T cells drive chronic inflammatory response. Self-
reactive T-cells might arise in Rheumatoid arthritis from Abnormal 
central selection due to defects in DNA repair leading to Imbalance of T-
cell death and life or defects in cell signalling apparatus lowering  
threshold for T-cell activation. Clinical diagnosis of Rheumatoid arthritis 
is largely based on signs and symptoms of chronic inflammatory arthritis, 
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with laboratory and radiographic results providing supplemental 
information.  
Collaborative effort between American College of Rheumatology 
(ACR) and European League Against Rheumatism (EULAR) revised the 
1987 ACR classification criteria for Rheumatoid arthritis in 2010,in an 
effort to improve early diagnosis with the goal of identifying patients  
who benefit from early introduction of disease-modifying therapy. 
Application of  newly revised criteria yields a score of  0–10, with a score 
of ≥ 6 fulfilling the requirements for definite Rheumatoid arthritis. The 
new classification criteria differs in several ways from older criteria. 
The new criteria include positive test for serum anti-CCP 
antibodies (ACPA--anti-citrullinated peptide antibodies) as an item, 
which carries greater specificity for diagnosis of Rheumatoid arthritis 
than positive test for Rheumatoid factor. 
The newer classification criteria do not take into account whether 
the patient has rheumatoid nodules or radiographic joint damage because 
the findings occur rarely in early Rheumatoid arthritis. 
It is important to emphasize, the new 2010 ACR-EULAR criteria 
are “classification criteria” as opposed to “diagnostic criteria” and serve 
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to distinguish patients at the onset of disease who have high likelihood of 
evolution to chronic disease with persistent synovitis and joint damage. 
The presence of radiographic joint erosions or subcutaneous nodules may 
inform the diagnosis in later stages of disease. 
1987-REVISED CLASSIFICATION CRITERIA11 
1. Morning stiffness in and around joints, atleast 1 hour before 
maximal Improvement. 
2. Arthritis of 3 or more joint areas. 
3. Symmetric arthritis 
4. Arthritis of Hand joints (wrist, MCPs, PIPs) 
5. Rheumatoid nodules 
6. Rheumatoid Factor 
7. Radiographic changes in hand and wrist joints. 
Requirements: > of the above 7 criteria. Criteria 1-4 must be 
present for atleast 6 weeks.  
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JOINT 
INVOLVEMENT 
 
1-Large joint (shoulder, elbow, hip, 
knee, ankle) 
 
2-10 large joints 
 
1-3 small joints (MCP,PIP, Thumb IP, 
MTP, wrist) 
 
4-10 small joints  
 
>10 joints (atleast 1 small joint) 
SCORE 
 
0 
 
1 
 
2 
 
3 
 
5 
SEROLOGY Negative RF and negative Anti-CCP 
 
Low positive RF or low positive anti-
CCP antibodies (< 3 times ULN) 
 
 High  positive RF or high positive 
anti-CCP antibodies (>3 times ULN) 
 
 
0 
 
2 
 
 
3 
ACUTE PHASE 
REACTANTS 
 
 
DURATION OF 
SYMPTOMS 
 Normal CRP and normal ESR 
 
Abnormal CRP or abnormal ESR 
 
<6 weeks 
 
> 6 weeks 
0 
 
1 
 
0 
 
1 
 
CLASSIFICATION CRITERIA FOR RHEUMATOID ARTHRITIS 
Note:  These  criteria  are  aimed  at  classification  of   newly 
presenting patients who have at least one joint with definite clinical 
synovitis that is not better explained by another disease. A score of 
≥6 fulfills requirements for definite RA. 
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DIAGNOSTIC MARKERS 
Patients with systemic inflammatory diseases such as Rheumatoid 
arthritis will most often present with elevated nonspecific inflammatory 
markers such as ESR or CRP. Detection of serum RF and anti-CCP 
antibodies is most important in differentiating Rheumatoid arthritis from 
other polyarticular diseases, although RF lacks diagnostic specificity and 
may be seen in association with other  chronic inflammatory diseases in 
which arthritis figures in clinical manifestations. 
 Serum IgM RF has been found in 75–80% of patients with 
Rheumatoid arthritis, therefore a negative result does not exclude 
presence of this disease. It is also found in other connective tissue 
diseases, like primary Sjögren’s syndrome, systemic lupus erythematosus 
and type II mixed essential cryoglobulinemia and also in chronic 
infections such as subacute bacterial endocarditis and hepatitis B and C. 
   Serum RF also be detected in 1–5% of  the healthy population. 
The presence of serum anti-CCP antibodies has the same sensitivity as 
serum RF for diagnosing Rheumatoid arthritis, but its diagnostic 
specificity approaches 95%, so a positive test for anti-CCP antibodies in 
the setting of early inflammatory arthritis is useful for distinguishing 
Rheumatoid arthritis  from other forms of arthritis. 
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Testing  for the presence of both RF and anti-CCP,  has some 
incremental effect as some patients with Rheumatoid arthritis are positive 
for RF but negative for anti-CCP and visa versa. 
The presence of RF or anti-CCP antibodies has some prognostic 
significance, with anti-CCP antibodies showing the most value for 
predicting worse outcomes. 
PERIPHERAL NEUROPATHY: 
Patients with connective tissue diseases including Rheumatoid 
arthritis have different types of peripheral  neuropathy like entrapment 
neuropathy, distal axonal, predominantly sensory polyneuropathy, 
mononeuropathy or multiple mononeuropathy, as well as fulminant 
sensorimotor polyneuropathy. When associated with Rheumatoid 
arthritis, vasculitis explain nerve injuries possibly by immune complex 
mediated damage to the vessel wall or myelinated nerves in some 
patients. Other possible causes for neuropathy may be mechanical 
affection of nerves by swelling of soft tissue, bone erosions and joint 
deformity or rheumatic nodules . Peripheral neuropathy associated with 
other connective tissue diseases like systemic lupus erythematosus and 
Sjogren’s syndrome is more frequently reported than Rheumatoid 
arthritis. 
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Peripheral nerves are composed of sensory, motor, and autonomic 
nerve fibres. Diseases can affect cell body of a neuron or its peripheral 
processes, the axons or the encasing myelin sheaths. Peripheral nerves are 
mostly mixed type and contain sensory and motor as well as autonomic 
fibers.  
Nerves are subdivided into three major classes: large myelinated, 
small myelinated, and small unmyelinated. Motor axons are most often 
large myelinated fibers that conduct rapidly approximately 50 m/s. 
Sensory fibers may be any of the three types described above. Large-
diameter sensory fibers conduct- proprioception and vibratory sensation 
to the brain, while the  smaller-diameter myelinated and unmyelinated 
fibers transmit- pain and temperature sensation. Autonomic nerves are  
small in diameter. Thus, peripheral neuropathies impair sensory, motor or 
autonomic function, either singly or in combination. 
Peripheral neuropathies are classified further into those that 
primarily affect the cell body (neuronopathy or ganglionopathy), myelin 
(myelinopathy), and axon (axonopathy). The different classes of 
peripheral neuropathies have distinct clinical and electrophysiologic 
features which is of practical significance. 
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Assessment of peripheral nerve function is important in detecting 
extraarticular neurological manifestations of Rheumatoid arthritis.  
Systemic vasculitis in Rheumatoid arthritis has been reported to increase 
the prevalence of peripheral neuropathy. 
Assessment of amplitude of the motor and sensory nerves reflects 
both the number of fibres conducting and their degree of synchrony, 
while distal latency and conduction velocity measures conduction in the 
fastest myelinated motor nerve fibres. Slowing of conduction velocity 
reflects segmental myelin loss. Conduction of the proximal segments can 
be measured using F wave responses. Peripheral neuropathy associated 
with other connective tissue diseases like, systemic lupus erythematosus 
and Sjogren’s syndrome is more frequently reported than in Rheumatoid 
arthritis. Peripheral neuropathy manifested as diffuse sensorimotor 
neuropathy  or mononeuritis multiplex occurs in a small subset of patients 
with RA.  The underlying mechanism is small-vessel vasculitis with 
ischemic neuropathy9  
In pathology of  mononeuropathies, our knowledge is somewhat 
more complete. Compression of nerve or its roots, local or segmental 
ischemia, stretch, and laceration of nerves are understandable 
mechanisms and their pathologic changes can be reproduced 
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experimentally. Tumor infiltration and importantly, vasculitis with 
ischemic infarction of nerve account for a proportion of cases of 
mononeuropathies. 
Polyneuropathies  are the result of axonal damage are characterized 
foremost by a relatively symmetric distribution of weakness that is, distal 
because the pathologic changes begin in the far distal parts of the largest 
and longest nerves and advance along the affected fibers toward their 
nerve cell bodies (dying-back neuropathy or "distal axonopathy")8.  
Muscles of the feet and legs are typically affected earlier and more 
severely than those of the hands and forearms. In milder forms of disease, 
only the feet and lower legs are involved. This shows the "length-
dependent" pattern that is typical of axonal degeneration. The nutritional, 
metabolic, and toxic neuropathies assume this predominantly distal 
"axonal" pattern. 
Some 1 to 5 percent of patients with rheumatoid arthritis have 
vasculitic involvement of one or more nerves at some point of time in 
their disease course8, apart from more mundane pressure neuropathies as 
a result of thickened tendons and destructive joint changes. 
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BRACHIAL ARTERIOGRAM SHOWING WIDESPREAD 
OCCLUSION OF DIGITAL VESSELS10. 
The arteritis is of small-vessel fibrinoid type and immune globulins 
are demonstrable in the walls of blood vessels. Most of the neuropathic 
patients under our care have had severe rheumatic disease for many years 
and were strongly seropositive8. In addition to neuropathy, such patients 
often have rheumatoid Nodules, skin vasculitis, weight loss, and fever. 
The diagnosis of these group of neuropathies depends on the finding of 
motor, reflex, and sensory changes confined to the territory of a single 
nerve; of several individual nerves affected in a random manner 
(mononeuritis or mononeuropathy multiplex); or a plexus of nerves or 
part of a plexus (plexopathy).  
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 Compression of median nerve at the wrist (carpal tunnel 
syndrome) is the most common disorder affecting the median nerve and 
itsthe most frequent nerve entrapment syndrome. The problem arises 
usually as a result of excessive use of hands and occupational 
microtrauma. Infiltration of the transverse carpalligament with amyloid 
(as occurs in multiple myeloma and amyloidosis) or thickening of 
connective tissue in rheumatoid arthritis leads on to clinical features of 
carpal tunnel syndrome. 
According to Kremer and colleagues, it was McArdle, in 1949, 
who first suggested the cause of this syndrome was compression of  
median nerve at the wrist and that the symptoms would be relieved by 
division of  flexor retinaculum forming the ventral wall of the carpal 
tunnel. Dysesthesias and pain in the fingers, referred to for many years as 
"acroparesthesia" came to be recognized as syndrome of median nerve 
compression only in early 1950. The syndrome is essentially sensory one. 
The loss or impairment of superficial sensation affects  palmar aspect of 
the thumb, the index and middle fingers  especially the index finger and 
may or may not split the ring finger. Electrophysiologic testing confirms 
the diagnosis by demonstrating prolonged sensory conduction across the 
wrist. Surgical division of the carpal liga-ment with decompression of the 
nerve is curative but is required only in severe and protracted cases. Most 
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often, splinting and local steroid injections are very satisfactory in the 
short-term, especially if the symptoms are of recent onset. 
ENTRAPMENT  NEUROPATHY : 
Reference has been made in several places in the preceding pages 
about the most frequently encountered entrapment neuropathies. A nerve 
passing through the tight canal is trapped and subjected to constant 
movement or pressure, forces not applicable to nerves elsewhere. The 
epineurium and perineurium become greatly thickened, strangling the 
nerve with additional possibility of demyelination 
 
ARTERY WITHIN EPINEURIUM OF RIGHT POSTERIOR 
TIBIAL NERVE WITH SEGMENTAL DESTRUCTION OF WALL 
AND FIBROUS INTIMAL THICKENING ENCROACHING ON 
THE LUMEN 
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. 
Function is gradually impaired with sensory more than motor, and 
the symptoms fluctuate with activity and rest. The most frequently 
compressed nerves are median, ulnar, peroneal, tibial, and plantar in 
approximately that order. It is well to keep in mind that the systemic 
processes that enhance pressure palsies by infiltration of the nerve or 
surrounding tissues. Peripheral entrapment neuropathy, which tends to 
occur when the nerve is compressed by inflamed synovium against a 
fixed structure. Atlantoaxial subluxation may cause neurologic 
impairment in patients with Rheumatoid arthritis9. 
As with other extraarticular complications of Rheumatoid arthritis, 
earlier and more aggressive treatment of Rheumatoid arthritis has resulted 
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in  decreased prevalence of neurologic complications that may be a result 
of disease activity. Mononeuritis multiplex is the least frequent 
neuropathies encountered in RA patients than other neuropathies and it is 
associated with high disease activity and requires immunosuppressive 
therapy. But the distal axonal sensory or sensorimotor polyneuropathies 
have been reported more frequently (up to 10% of RA patients) and are 
associated with lower disease activity and have an excellent prognosis. It 
can be managed symptomatically.  
Compressive neuropathies are the most common neuropathies and 
they are described in 20% to 70% of patients.  Carpal tunnel syndrome --
affecting the median nerve and tarsal tunnel syndrome --affecting the 
posterior tibial nerve are the most common compressive neuropathies, 
respectively presenting as numbness in the first three digits of hands and 
feet. Compression neuropathies results from synovial or bursa 
inflammation or can occur due to joint deformities or posttraumatic 
fibrosis not stemming from active disease. Conservative strategies 
including splinting and tendon sheath injections, are tried before surgical 
release. In contrast to compressive neuropathies, inflammatory 
demyelinating neuropathies have been temporally associated with the use 
of tumor necrosis factor (TNF) inhibitors 9. Despite the rarity of these 
inflammatory demyelinating neuropathies described in lesser than 100 
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RA patients treated with TNF inhibitors, such demyelinating neuropathies 
are otherwise not seen in RA patients, and therefore an etiopathogenic 
relationship is suggested. Some patients show improvement or 
stabilization when the offending TNF inhibitors are withdrawn, other 
patients require treatment with intravenous immunoglobulin or other 
therapies used for the treatment of primary demyelinating neuropathies.9 
DRUGS CAUSING PERIPHERAL NEUROPATHY: 
LEUFLONAMIDE 
Leflunomide side effects include headache, dizziness, and 
paresthesia. The central nervous system adverse effects are usually mild 
to moderate and are not commonly a cause for stopping the drug. Case 
reports of peripheral neuropathy associated with leflunomide have been 
reviewed. Of 80 reported cases, symptoms began after a mean of 6 
months of treatment. Electrodiagnosis was consistent with distal axonal, 
sensory, or sensorimotor polyneuropathy in most patients. Patients 
withdrawing from leflunomide within 30 days were more likely to show 
improvement. In a study to monitor potential clinical neurotoxicity in 113 
patients treated with leflunomide, eight incident cases of peripheral 
neuropathy and two cases of worsening of preexisting neuropathy were 
diagnosed by nerve conduction studies .Compared with patients not 
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receiving leflunomide, patients receiving leflunomide were older (mean 
age, 69), most often diabetic (30%), and most often treated with 
potentially neurotoxic drugs (20%). Atleast one risk factor was found in 
about 50% of patients with neuropathy  (positive predictive value- 56%; 
negative predictive value- 96%). The results suggest the need for careful 
monitoring of  patient’s neurologic status during leflunomide treatment. 
Patients became stable  symptomatically and electrophysiologically on 
cessation of the drug. 
PYRIDOXINE (VITAMIN B6) TOXICITY: 
Pyridoxine is an essential vitamin that serves as a coenzyme for 
transamination and decarboxylation process. But, at high doses (116 
mg/d), patients may develop severe sensory neuropathy with dysesthesias 
and sensory ataxia. Nerve conduction study reveal absent or markedly 
reduced Sensory nerve action potential amplitudes with relatively 
preserved compound motor action potentials. Nerve biopsy reveals 
axonal loss of fiber of all diameters. 
ISONIAZID : 
Most common side effects of isoniazid (INH) is peripheral 
neuropathy. Standard doses of INH (3–5 mg/kg per day) are associated 
with 2% incidence of neuropathy, whereas incidence of neuropathy 
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increases to at least 17% of patients taking excess of 6 mg/kg per day. 
Elderly, malnourished, and “slow acetylators” are at increased risk for 
developing peripheral neuropathy. INH inhibits pyridoxal phosphokinase, 
resulting in pyridoxine deficiency and leading on to neuropathy. 
Prophylactic administration of pyridoxine 100 mg/d can prevent the 
development of neuropathy. 
ANTIRETROVIRAL AGENTS  
The nucleoside analogues like zalcitabine (dideoxycytidine or 
ddC), didanosine (dideoxyinosine or ddI), stavudine (d4T), lamivudine 
(3TC), and antiretroviral nucleoside reverse transcriptase inhibitor 
(NRTI) are used to treat HIV infection. The  dose-limiting side effects of 
these medications is predominantly sensory, length-dependent, 
symmetrically painful neuropathy. Zalcitabine (ddC), at doses greater 
than 0.18 mg/kg per day, is associated with sub acute onset of severe 
burning and lancinating pains in feet and hands. NCS revealed decreased 
amplitudes of the sensory nerve action potentials with normal motor 
conduction studies. Nucleoside analogues inhibit mitochondrial DNA 
polymerase, which is the suspected pathogenic basis for the neuropathy. 
Because of “coasting effect,” patients continue to worsen even 2–3 weeks 
after stopping the medication. Following dose reduction, improvement in 
the neuropathy is seen in most patients several months later. NCS reveals 
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absent or markedly reduced Sensory nerve action potential amplitudes 
with relatively preserved CMAPs. 
NUTRITIONAL NEUROPATHIES COBALAMIN (VITAMIN 
B12): 
Pernicious anemiais  most commonly caused by the  deficiency of 
cobalamin. Other causes includes dietary avoidance, gastrectomy, gastric 
bypass surgery, inflammatory bowel disease, pancreatic insufficiency, 
bacterial overgrowth, and possibly histamine-2 blockers and proton pump 
inhibitors. An under appreciated cause of cobalamin deficiency is food-
cobalamin malabsorption which typically occurs in older individuals and 
results from an inability to adequately absorb cobalamin from food 
protein. The use of nitrous oxide as anesthetic agent or as recreational 
drug can produce acute cobalamin deficiency neuropathy and subacute 
combined degeneration. Preferentially  large-fiber sensory loss affecting 
proprioception and vibration with sparing of small-fiber modalities is 
present. Diagnosis is confirmed by reduced serum cobalamin levels. 
Antibodies to intrinsic factor is present in approximately 60%, and 
antiparietal cell antibodies in about 90%, of individuals with pernicious 
anemia.  
  
 
38 
Cobalamin deficiency is treated with various regimens of 
cobalamin. One regimen consists of 1000 μg of cyanocobalamin IM 
weekly for 1 month and monthly thereafter. Patients with food cobalamin 
malabsorption can absorb free cobalamin and therefore can be treated 
with oral cobalamin supplementation. An oral cobalamin dose of 1000 μg 
per day should be sufficient. Treatment for cobalamin deficiency usually 
does not reverse the clinical manifestations completely and at least 50% 
of patients exhibit some permanent neurologic deficit. 
THIAMINE DEFICIENCY 
Thiamine deficiency now most often seen as a consequence of 
chronic alcohol abuse, recurrent vomiting and total parenteral nutrition 
leading to peripheral neuropathy. Beriberi means “I can’t, I can’t” in 
Singhalese. Dry beriberi refers to the neuropathic symptoms. Wetberiberi 
is used when cardiac manifestations predominate in reference to edema. 
Symptoms of neuropathy follow prolonged deficiency and these begin 
with mild sensory loss and burning dysesthesias in the toes and feet and 
aching and cramping in the lower legs. Patients develop features of a 
nonspecific generalized polyneuropathy, with distal sensory loss in the 
feet and hands. Thiamine is given intravenously or intramuscularly at a 
dose of 100 mg/d. Neurologic improvement is usually more variable and 
less dramatic. 
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VITAMIN  E DEFICIENCY :  
Clinical features may not appear until many years after the onset of 
deficiency. Symptoms onset tends to be insidious, and progression is 
slow. Main clinical features are spinocerebellar ataxia and 
polyneuropathy. Vitamin E deficiency may present as an isolated 
polyneuropathy, but it’s very rare. Diagnosis is made by measuring alpha-
tocopherol levels in the serum. Electrodiagnosis shows features of axonal 
neuropathy. Treatment is with replacement of oral vitamin E 1500–6000 
IU/d in divided doses. 
VITAMIN B6 DEFICIENCY : 
Vitamin B6 or pyridoxine, can produce neuropathic manifestations 
from both deficiency and toxicity as discussed above. Vitamin B6 
deficiency is commonly seen in patients treated with isoniazid or 
hydralazine. The polyneuropathy of vitamin B6 is nonspecific and 
manifesting as generalized axonal sensorimotor  polyneuropathy. Vitamin 
B6 deficiency is detected by direct assay. Vitamin B6 supplementation 
with 50–100 mg/d is suggested for patients being treated with isoniazid or 
hydralazine and also for replacement in cases of nutritional deficiency. 
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NIACIN DEFICIENCY: 
Pellagra is produced by deficiency of niacin. Pellagra may be seen 
in alcoholics. Neurologic manifestations are variable; abnormalities can 
develop in the brain and spinal cord as well as peripheral nerves. When 
peripheral nerves are involved, the neuropathy is usually mild and 
resembles that of beriberi. 
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MATERIALS AND METHODS 
STUDY DESIGN : Cross sectional study 
STUDY PERIOD : 8 months 
STUDY AREA            :  Govt. Kilpauk Medical College, Chennai. 
STUDY POPULATION:  
Rheumatoid arthritis patients in OPD and admitted in Govt. 
Kilpauk Medical College & Hospital, Chennai. 
SAMPLE SIZE  :        60 
SOURCE OF DATA  :      The present study will be conducted in the                                            
Department of Medicine and Rheumatology, Govt.  KMCH, Chennai. 
Rheumatoid arthritis patients attending OPD or admitted to the 
hospital will be taken for the study. 
METHOD OF COLLECTION OF DATA:  
Definition of study  
Study subjects  :  Sixty  patients attending OPD or admitted to the 
hospital with diagnosis of rheumatoid arthritis, with or without clinical 
evidence of neuropathy, satisfying the inclusion and exclusion criteria 
will be taken for the study.  
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Inclusion criteria 
Patients already diagnosed as Rheumatoid Arthritis as                                   
Per 1987 Revised ACR Classification Criteria and correlated with 
laboratory data.  
Exclusion criteria:  
1.      Diabetes mellitus 
2.       Renal failure 
3.       Chronic alcoholism  
4.       Retro viral disease 
5.      Liver disease 
6.      Thyroid disease 
7.       Pregnancy 
8.       Drugs 
STUDY METHODS:  The present study is a clinical study.  
1.  The study period is from   date of ethical clearance to 8 months.  
2. A total of 60  rheumaroid arthritis patients are taken for study. 
3. All these patients are evaluated thoroughly by clinical,  laboratory 
methods. All patients will undergo nerve conduction study of 
median nerve, ulnar nerve, common peroneal nerve and sural 
nerves. 
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4.    Compound muscle action potential, sensory nerve action potential, 
distal and proximal latencies and nerve conduction velocities are 
studied. 
INVESTIGATIONS NEEDED FOR THE STUDY   
• Hb%, TC, DC, ESR, platelet count. 
• CRP,  RF/Anti CCP Factor. 
Electrophysiological studies  
Nerve conduction studies were performed using the Medelec-
Synergy EMG instrument . The skin temperature kept between 31and 32 
degree Celsius. Nerve velocity increases by 2.4m/s per degree from 29 to 
38°C skin temperature12-18 
 Median, ulnar, peroneal, and posterior tibial motor nerve 
conduction studies (NCSs), including F-waves, were performed on both 
sides. 
Median, ulnar, superficial peroneal, and sural sensory NCSs were 
performed on both sides. Latency of the H-wave was measured 
bilaterally. Motor nerve conduction was performed using the bellytendon 
method. Sensory nerve conduction was studied antidromically. 
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 All amplitudes were determined based on the base-to-peak value;. 
The conduction velocity of each nerve was measured. Findings were 
compared with the reference values used in our center . 
Polyneuropathy was diagnosed when at least three Abnormal  
parameters were present. When the median CMAP latency was greater 
than 4.2 ms or the median SNAP was greater than 3.6 ms, we used the 
‘mid-palm’ technique to diagnose carpal tunnel syndrome (CTS). The 
median nerve was then stimulated at the palm at a 14-cm distance (wrist). 
Presence of CTS was considered when the ratio of palm to wrist latency 
was lower than 50%. All of the patients gave informed consent, and the 
study was approved by the ethics committee of our university. The 
clinical and laboratory findings were analysed. 
NERVE LATENCY 
(ms) 
AMPLITUDE CONDUCTION 
VELOCITY(m/s) 
MOTOR 
Median 
Ulnar 
Deep 
Peroneal 
Posterior 
Tibial 
 
<4.2 
<4.2 
<6.2 
 
<5 
 
>5 
>5 
>2 
 
>5 
 
>50 
>50 
>40 
 
>40 
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NERVE LATENCY 
(ms) 
AMPLITUDE CONDUCTION 
VELOCITY(m/s) 
F- WAVE 
Median 
Ulnar 
Deep 
Peroneal 
Posterior 
Tibial 
 
<30 
<30 
<50 
 
<50 
 
- 
- 
- 
 
- 
 
- 
- 
- 
 
- 
SENSORY 
Median 
Ulnar 
Superficial 
Peroneal 
Sural 
 
<3.6 
<3.6 
<4.2 
 
<3.9 
 
>20 
>10 
>5 
 
>10 
 
- 
- 
- 
 
- 
H-REFLEX <32 - - 
 
Reference values for nerve conduction study used in the present 
study 
1. Peak latencies of all sensory nerves 
2. Onset latencies of all motor nerves.  
3. Amplitudes are measured in millivolt (mV, motor) and in 
  microvolt (μV, sensory). 
Statistical Analysis:  
Statistical analysis done by Fishers  exact test, Unpaired-t test. 
Multivariate analysis of factors determined by logistic regression. P value 
<0.05 is taken as significant correlation with confidence interval of 95%. 
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OBSERVATION AND RESULTS 
Study Subjects 
 
Study Subjects Number Percentage 
PN +ve 26 43.33 
PN -ve 34 56.67 
Total 60 100.00 
  
26, 43%
34, 57%
Study Subjects
PN +ve
PN -ve
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Types of Neuropathy based on Nerve Conduction Study 
 
Types of Neuropathy based on Nerve 
Conduction Study 
Number Percentage 
Sensory Motor Neuropathy 11 42.31 
Mononeuritis Multiplex 2 7.69 
Sensory Neuropathy 6 23.08 
Motor Neuropathy 5 19.23 
Carpel Tunnel Syndrome 2 7.69 
Total 26 100.00 
 
11, 42%
2, 8%
6, 23%
5, 19%
2, 8%
Types of Neuropathy based on Nerve 
Conduction Study
Sensory Motor Neuropathy
Mononeuritis Multiplex
Sensory Neuropathy
Motor Neuropathy
Carpel Tunnel Syndrome
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Age 
 
Age 
Groups 
PN +ve % PN -ve % Overall % 
≤ 30 years 1 3.85 5 14.71 6 10.00 
31-40 
years 
6 23.08 20 58.82 26 43.33 
41-50 
years 
12 46.15 8 23.53 20 33.33 
51-60 
years 
6 23.08 1 2.94 7 11.67 
61-70 
years 
1 3.85 0 0.00 1 1.67 
Total 26 100.00 34 100.00 60 100.00 
 
1
6
12
6
1
5
20
8
1 0
6
26
20
7
1
0
5
10
15
20
25
30
≤ 30 years 31-40 years 41-50 years 51-60 years 61-70 years
Age Groups
PN +ve PN -ve Overall
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Age Distribution PN +ve PN -ve Overall 
Mean 45.85 36.65 40.63 
SD 8.99 6.87 9.04 
P value 
Unpaired t Test 
<0.0001 
 
It is evident from the age distribution table that most of the PN +ve 
group subjects were in 41-50 years age group (46.15%) with a mean age 
of 45.85 years. Similarly in PN -ve group majority were in 31-40 years 
age group (58.82%) with a mean age of 36.65 years. (p= <0.0001). The 
data subjected to unpaired t test reveals the existence of statistically 
significant association between age distribution and intervention groups 
(p < 0.05) 
In our study age distribution between the PN +ve group and PN –
ve group was meaningfully significant. This is evident by the increased 
mean age in PN +ve group compared to PN –ve group (mean difference 
of 9.20 years, 20% higher). Age is a known risk factor for 
polyneuropathy 19 
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Gender 
 
Gender 
Status 
PN 
+ve 
% PN -
ve 
% Overall % 
Male 7 26.92 4 11.76 11 18.33 
Female 19 73.08 30 88.24 49 81.67 
Total 26 100.00 34 100.00 60 100.00 
P value 
Fishers Exact Test 
0.1329 
 
It is evident from the gender status table that most of the PN +ve 
group subjects were females (73.08%) and in PN -ve group majority too 
were females (88.24%) (p= 0.1329). The data subjected to fishers exact 
test reveals the existence of statistically insignificant association between 
gender status and intervention groups (p >0.05) 
7
19
4
30
11
49
0
10
20
30
40
50
60
Male Female
Gender Status
PN +ve PN -ve Overall
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Hb 
 
Hemoglobin 
Groups 
PN +ve % PN -
ve 
% Overall % 
≤ 9 gm % 1 3.85 1 2.94 2 3.33 
9.1-11 gm % 7 26.92 13 38.24 20 33.33 
11.1-13 gm 
% 
13 50.00 15 44.12 28 46.67 
13.1-15 gm 
% 
5 19.23 5 14.71 10 16.67 
Total 26 100.00 34 100.00 60 100.00 
 
 
1
7
13
5
1
13
15
5
2
20
28
10
0
5
10
15
20
25
30
≤ 9 gm % 9.1-11 gm % 11.1-13 gm % 13.1-15 gm %
Hemoglobin Groups
PN +ve PN -ve Overall
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Hemoglobin 
Distribution 
PN +ve PN -ve Overall 
Mean 11.68 11.59 11.63 
SD 1.53 1.44 1.47 
P value 
Unpaired t Test 
0.8231 
 
It is evident from the hemoglobin distribution table that most of the 
PN +ve group subjects were in 11.1-13 gm % group (50%) with a mean 
Hb of 11.68 gm%. Similarly in PN -ve group majority were in 11.1-13 
gm % group (44.12%) with a mean Hb of 11.59 gm% (p= 0.8231). The 
data subjected to unpaired t test reveals the existence of statistically 
insignificant association between age distribution and intervention groups 
(p > 0.05) 
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ESR 
 
ESR Groups PN 
+ve 
% PN -
ve 
% Overall % 
≤ 20 mm/hr 1 3.85 7 20.59 8 13.33 
21-40 mm/hr 17 65.38 23 67.65 40 66.67 
41-60 mm/hr 7 26.92 4 11.76 11 18.33 
61-80 mm/hr 0 0.00 0 0.00 0 0.00 
81-100 
mm/hr 
1 3.85 0 0.00 1 1.67 
Total 26 100.00 34 100.00 60 100.00 
 
1
17
7
0 1
7
23
4
0 0
8
40
11
0 1
0
5
10
15
20
25
30
35
40
45
≤ 20 mm/hr 21-40 mm/hr 41-60 mm/hr 61-80 mm/hr 81-100 mm/hr
ESR Groups
PN +ve PN -ve Overall
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ESR Distribution PN +ve PN -ve Overall 
Mean 39.77 28.97 33.65 
SD 14.48 8.63 12.63 
P value 
Unpaired t Test 
0.0007 
 
It is evident from the ESR distribution table that most of the PN 
+ve group subjects were in 21-40 mm/hr group (65.38%) with a mean 
ESR of 39.77 mm/hr. Similarly in PN -ve group majority were in 21-40 
mm/hr group (67.65%) with a mean ESR of 39.77 mm/hr. (p= 0.0007). 
The data subjected to unpaired t test reveals the existence of statistically 
significant association between ESR distribution and intervention groups 
(p < 0.05) 
In our study ESR distribution between the PN +ve group and PN –
ve group was meaningfully significant. This is evident by the increased 
mean ESR in PN +ve group compared to PN –ve group (mean difference 
of 10.80 mm/hr, 27% higher).  
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CBC 
 
Complete Blood 
Count 
Total 
Count 
Polymorphs Lymphocytes Monocytes Platelets 
PN +ve Mean 9073.08 67.96 29.35 2.96 2.73 
SD 1708.59 5.64 5.95 1.84 0.77 
PN -ve Mean 9132.35 69.26 27.15 3.00 2.42 
SD 2249.00 7.97 7.34 2.89 0.82 
P value 
Unpaired t Test 
0.9113 0.4814 0.2178 0.9530 0.1421 
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.0
8
67
.9
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It is evident from the complete blood count distribution table that 
the mean total count, polymorphs count, lymphocytes count, monocytes 
count and platelets count were 9073.08, 67.96, 29.35, 2.96 and 2.73. 
Similarly in PN -ve group it was 9132.35, 69.26, 27.15, 3.00 and 2.42.  
(p= 0.9113, 0.4818, 0.2178, 0.9530 and 0.1421). The data subjected to 
unpaired t test reveals the existence of statistically insignificant 
association between complete blood count distribution and intervention 
groups (p > 0.05) 
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CRP 
 
C-Reactive 
Protein Status 
(mg/dl) 
PN 
+ve 
% PN -
ve 
% Over 
all 
% 
Negative 11 42.31 15 44.12 26 43.33 
Positive 15 57.69 19 55.88 34 56.67 
Total 26 100.00 34 100.00 60 100.00 
P value 
Fishers Exact Test 
0.8891 
 
 
11
1515
19
26
34
0
5
10
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30
35
40
Negative Positive
C-Reactive Protein Status (mg/dl)
PN +ve PN -ve Overall
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It is evident from the C reactive protein status table that most of the 
PN +ve group subjects were CRP negative (57.69%) and in PN -ve group 
majority too were CRP negative (55.88%) (p= 0.8891). The data 
subjected to fishers exact test reveals the existence of statistically 
insignificant association between C reactive protein status and 
intervention groups (p >0.05) 
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RF 
 
Rheumatoid 
Factor Status 
PN 
+ve 
% PN -ve % Overall % 
Negative 1 3.85 11 32.35 12 20.00 
Positive 25 96.15 23 67.65 48 80.00 
Total 26 100.00 34 100.00 60 100.00 
P value 
Fishers Exact Test 
0.0064 
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 It is evident from the rheumatoid factor status table that most of 
the PN +ve group subjects were RA factor positive (96.15%) and in PN -
ve group majority too were RA factor positive (67.65%) (p= 0.8891). The 
data subjected to fishers exact test reveals the existence of statistically 
significant association between rheumatoid factor status and intervention 
groups (p <0.05) 
In our study rheumatoid factor status between the PN +ve group 
and PN –ve group was meaningfully significant. This is evident by the 
increased incidence of RA factor positivity in PN +ve group compared to 
PN –ve group (percentage difference of 28.51, 30% higher).  
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Anti-CCP Antibody 
 
Anti-CCP 
Antibody 
Status 
PN +ve % PN -
ve 
% Overall % 
Negative 18 69.23 31 91.18 49 81.67 
Positive 8 30.77 3 8.82 11 18.33 
Total 26 100.00 34 100.00 60 100.00 
P value 
Fishers Exact Test 
0.0288 
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It is evident from the anti CCP antibody status table that most of 
the PN +ve group subjects were anti CCP antibody negative (69.23%) 
and in PN -ve group majority too were anti CCP antibody negative 
(91.18%) (p= 0.0288). The data subjected to fishers exact test reveals the 
existence of statistically significant association between anti CCP 
antibody status and intervention groups (p <0.05) 
In our study anti CCP antibody status between the PN +ve group 
and PN –ve group was meaningfully significant. This is evident by the 
increased incidence of anti CCP antibody positivity in PN +ve group 
compared to PN –ve group (percentage difference of 21.95, 71% higher).  
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Duration of RA 
 
Duration 
of RA 
Groups 
PN +ve % PN -
ve 
% Overall % 
≤ 5 years 6 23.08 23 67.65 29 48.33 
6-10 
years 
14 53.85 8 23.53 22 36.67 
11-15 
years 
5 19.23 3 8.82 8 13.33 
16-20 
years 
0 0.00 0 0.00 0 0.00 
> 20 
years 
1 3.85 0 0.00 1 1.67 
Total 26 100.00 34 100.00 60 100.00 
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Duration of RA 
Distribution 
PN 
+ve 
PN –ve Overall 
Mean 8.23 5.06 6.43 
SD 3.73 2.84 3.60 
P value 
Unpaired t Test 
0.0004 
 
It is evident from the duration of RA distribution table that most of 
the PN +ve group subjects were in 6-10 years group (53.85%) with a 
mean duration of RA of 8.23 years. Similarly in PN -ve group majority 
were in ≤ 5 years group (67.65%) with a mean duration of RA of 5.06 
years (p= 0.0004). The data subjected to unpaired t test reveals the 
existence of statistically significant association between duration of RA 
distribution and intervention groups (p < 0.05) 
In our study duration of RA distribution between the PN +ve group 
and PN –ve group was meaningfully significant. This is evident by the 
increased mean duration of RA in PN +ve group compared to PN –ve 
group (mean difference of 3.17 years, 39% higher).  
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Steroid 
 
Steroid 
Medication 
Status 
PN +ve % PN -ve % Overall % 
Yes 7 26.92 13 38.24 20 33.33 
No 19 73.08 21 61.76 40 66.67 
Total 26 100.00 34 100.00 60 100.00 
P value 
Fishers Exact Test 
0.3573 
 
It is evident from the steroid medication status table that most of 
the PN +ve group subjects did not take steroids (83.08%) and in PN -ve 
group majority too did the same (61.76%) (p= 0.3573). The data 
subjected to fishers exact test reveals the existence of statistically 
insignificant association between steroid medication status and 
intervention groups (p >0.05) 
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DMARDs 
 
DMARDs 
Medication 
Status 
PN 
+ve 
% PN -ve % Overall % 
Yes 26 100.00 24 70.59 50 83.33 
No 0 0.00 10 29.41 10 16.67 
Total 26 100.00 34 100.00 60 100.00 
P value 
Fishers Exact Test 
0.0022 
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It is evident from DMARDs medication status table that most of 
the PN +ve group subjects took DMARDs medication (100%) and in PN 
-ve group majority too took DMARDs medication (70.59%) (p= 0.0288). 
The data subjected to fishers exact test reveals the existence of 
statistically significant association between DMARDs medication status 
and intervention groups (p <0.05) 
In our study DMARDs medication status between the PN +ve 
group and PN –ve group was meaningfully significant. This is evident by 
the increased incidence of intake of DMARDs medication in PN +ve 
group compared to PN –ve group (percentage difference of 29.41, 29% 
higher).  
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Neuropathic Symptoms 
 
Neuropathic 
Symptoms 
Status 
PN +ve % PN -ve % Overall % 
Yes 5 19.23 2 5.88 7 11.67 
No 21 80.77 32 94.12 53 88.33 
Total 26 100.00 34 100.00 60 100.00 
P value 
Fishers Exact Test 
0. 1198 
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It is evident from the neuropathic symptoms status table that most 
of the PN +ve group subjects did not have neuropathic symptoms 
(80.77%) and in PN -ve group majority too did not have neuropathic 
symptoms (94.12%) (p= 0.1198). The data subjected to fishers exact test 
reveals the existence of statistically insignificant association between 
neuropathic symptoms status and intervention groups (p >0.05) 
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Multivariate analysis of factors associated with peripheral 
neuropathy in RA as determined by logistic regression 
Variable Odds ratio 95% CI P-value 
Age (> 40 years) 2.43 1.47-4.01 0.0112 
Gender (Male) 1.75 1.04-2.93 0.1141 
Hemoglobin> 11 
gm% 
1.02 0.85-2.87 0.1026 
ESR >40 mm/hr 2.65 1.67-4.79 0.0457 
CRP +ve Status 1.75 1.04-2.93 0.4421 
RF +ve Status 2 1.21-3.32 0.0966 
Anti-CCF Antibody 
+ve status 
3.49 0.88-5.87 0.0322 
Duration of RA > 
10 years 
2.07 0.74-4.47 0.0145 
Steroid Intake 2.15 0.87-3.39 0.6832 
DMARDs Intake 2.94 0.91-5.05 0.0751 
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Multivariate analysis demonstrated that after adjusting of basic 
variables and rheumatoid arthritis. 
• The risk of developing peripheral neuropathy in patients with 
rheumatoid arthritis is 2.43 times significantly more when age is 
greater than 40 years than in patients less than 40 years.    It is 
statistically significant with a p-value of 0.0112 
• The risk of developing peripheral neuropathy in patients with 
rheumatoid arthritis is 2.65 times significantly more when ESR is 
greater than 40 mm/hr than in patients less than 40 mm/hr.    It is 
statistically significant with a p-value of 0.0457 
• The risk of developing peripheral neuropathy in patients with 
rheumatoid arthritis is 1.49 times significantly more when anti 
CCF antibody positivity exists than in patients less than in patients 
with anti CCF antibody negativity.    It is statistically significant 
with a p-value of 0.0322 
• The risk of developing peripheral neuropathy in patients with 
rheumatoid arthritis is 2.07 times significantly more when the 
duration of RA is more than 10 years than in patients with less than 
10 years duration. It is statistically significant with a p-value of 
0.0145 
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DISCUSSION 
 
The prevalence of peripheral neuropathy and their relationship with 
demography, clinical findings, and laboratory values have not been 
clearly demonstrated in the literature. The prevalence of peripheral 
neuropathy vary among previous studies, as shown in Table below. 
Furthermore, it is difficult to compare studies on peripheral neuropathy in 
RA because the inclusion criteria and neuropathy assessment methods 
varies between previous studies. In our present study, we reported a 
frequency of peripheral neuropathy, including entrapment neuropathy of 
43.3% in RA patients, which appears to be lower than that in previous 
studies with a large series of patients. The frequency of peripheral 
neuropathy in our study was higher than the frequency of idiopathic 
polyneuropathy of 8%, reported previously in a population-based 
epidemiological study19. We included RA patients with neurological 
symptoms in our current study, the prevalence of neuropathy in the 
electrophysiological study was more than that in other studies. There was 
no relationship between the neuropathic symptoms and the presence of 
peripheral neuropathy, which may be because the neuropathic symptoms 
consists of questions that focus on positive symptoms, such as burning 
and tingling, which are subjectively reported by the patients and also 
neuropathic symptoms mimic the symptoms of arthritis. Because of all 
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these reasons, neuropathic symptoms of patients might show a poor 
correlation with results of electrophysiological studies. 
 
Comparison between electrophysiological studies of peripheral 
neuropathy and associated factors in the present and previous studies 
 
Study No. of 
patients 
Types of peripheral neuropathy 
SM S M MM CTS 
 
Associated factors 
Fleming 
etal. 29 
102 0       15    3     0        53 * 
Agarwal et 
al. 27 
108 25      28    0     7        11 Absence of DTR,  
Presence of vasculitis 
Lanzillo et 
al. 28 
40         26       0     0     0          3 * 
Nadkar et 
al.26 
31 6       0      4     4         1 * 
Bayrak et al. 
30 
60 8      2      0      0         * Duration of RA, NSS, 
NDS,   DAS 28 
Mi Kyung 
Sim, et al. 
30 2     1       0      0         7 Age, anti-CCP antibody 
Present 
study 
60 11    6       5      2         2 Age,ESR,Anti-
CCPantibodyDuration of 
RA 
 
SM  -  sensorimotor; S- sensory; M- motor;  
MM -  mononeuritis multiplex; 
CTS -  carpal tunnel syndrome;DTR- deep tendon reflex;  
RA  -  rheumatoid arthritis; NSS- neuropathy symptom score; 
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NDS- neuropathy disability score; DAS 28 - 28-joint disease 
activity score Anti-CCP - anti-cyclic citrullinated peptide. 
In present study we found significant correlation between 
peripheral neuropathy and the age of the patients, ESR, duration of RA 
and Anti-CCP antibodies. In present study, we did not find significant 
association between peripheral neuropathy and Gender, Neuropathic 
symptoms, CRP and type of medication. We found that RA patients with 
peripheral neuropathy were older than RA patients without peripheral 
neuropathy. Age is a known risk factor for polyneuropathy20, and RA 
patients with peripheral neuropathy in our study showed similar results. 
However, the prevalence of peripheral neuropathy in patients with RA in 
this study was higher than that of peripheral neuropathy in patients 
without the underlying disease. 
The most important finding of our study was that patients who 
were positive for anti-CCP antibody showed an increased risk of 
peripheral neuropathy. The anti-CCP antibody has become a focus of 
attention for diagnosis and it is a marker of severe RA21. New study 
reported that anti-CCP antibody is associated with human leukocyte 
antigen (HLA) class II RA-related susceptibility alleles and also with 
severe disease manifestations22. Some authors have observed a tendency 
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for positive association between anti-CCP antibody titer with 
extraarticular manifestations in RA, but there is no data on the effects of 
anti-CCP antibody on the development of peripheral neuropathy23-25. Our 
present study is one of the study to investigate the relationship between 
anti-CCP antibody and the development of peripheral neuropathy in RA 
patients. In our study anti CCP antibody status between the PN +ve group 
and PN –ve group was meaningfully significant. This is evident by the 
increased incidence of anti CCP antibody positivity in PN +ve group 
compared to PN –ve group (percentage difference of 21.95, 71% higher). 
Also, the effect of anti-CCP antibody on peripheral neuropathy seems to 
increase with age. Our study was limited by small sample size and cross-
sectional design. We were unable to conduct an electrophysiological 
study for the same duration from symptom onset. Also, we were unable to 
determine the definite cause of peripheral neuropathy and CTS in this 
study, whether it was due to direct nerve injury or due to joint deformity 
or it was an independent disease. Furthermore longitudinal studies in a 
large population are needed.. It is difficult to distinguish the symptoms of 
peripheral neuropathy and those of arthritis, also the subjective symptoms 
of patients do not correlate with electrophysiological results. Hence, 
electrophysiological studies should be performed in patients with RA, 
particular in older patients and anti-CCP antibody positive patients. 
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CONCLUSSION 
We can conclude that: 
Gender, hemoglobin levels, complete blood counts, CRP, steroid 
medication and neuropathic symptoms had no statistically significant role 
to play on deciding peripheral neuropathy in rheumatoid arthritis patients 
On internal comparison (PN +ve group and PN -ve group) the 
following conclusions were observed   
o Peripheral neuropathy in rheumatoid arthritis patients is common 
among higher age group 
o Enhanced ESR levels among rheumatoid arthritis patients with 
peripheral neuropathy  
o Higher incidence of RA factor positivity among rheumatoid 
arthritis patients with peripheral neuropathy  
o Higher incidence of Anti CCP antibody positivity among 
rheumatoid arthritis patients with peripheral neuropathy  
o Longer duration of RA in peripheral neuropathy patient in 
rheumatoid arthritis  is common among higher age group 
o Higher incidence of DMARDs medication among rheumatoid 
arthritis patients with peripheral neuropathy  
BIBILOGRAPHY 
1.       Pispati PK , Rheumatoid arthritis. Shah SN. API – Text book of medicine. 
The association of physicians of India.7th edition.2003; 1160-1164.  
2. Lipsky PE, Rheumatoid arthritis. Braunwald, Kasper D, Faucci A. 
Harrison's    Principles of internal Medicine,16thedition, McGraw Hill 
publications; 2004, 1968-1977.  
3.  Wollheim FA, Rheumatoid arthritis- the clinical picture:   Maddison PJ, 
David A, Isenberg, Patricia WOO and David NG. Oxford text of 
rheumatology. Oxford University press.1993; 1: 639-657. 
4. Nadkar MY, Agarwal R, Samant RS, Chhugani SJ, Idgunji SS, et al. 
Neuropathy in Rheumatoid arthritis. JAPI; 2001: 49: 217-220.  
5. Salih AM, Nixon NB, Gagan RM, Heath P, Hawkins CP, Dawes PT et al 
.Anti-ganglioside antibodies in patients with rheumatoid arthritis 
complicated by peripheral neuropathy. Brit. J. Rheum., 1996; 35:725-31..     
6. Ropper AH, Brown RH. Disease of peripheral nerves:  Ropper AH, 
Brown RH. Adam and Victor's Principles of Neurology: 8th edition, 
McGraw Hill publications, 2005;1139 
7. Harrison text book of internal medicine ,19th edition McGraw Hill 
publication. 
8. Adam  and victor’s principles of Neurology, 10th edition McGraw Hill 
publication. 
9. Rheumatology / [edited by] Marc C. Hochberg, Alan J. Silman, Josef S. 
Smolen, Michael E. Weinblatt, Michael H. Weisman.—Sixth edition.  p. ; 
cm.C. A. 10.PALLIS,* D.M., M.R.C.P.; J. T. SCOTT,t M.B., M.R.C.P   
Brit. med. J., 1965, 1, 1141-1147 
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, 
et al. The American Rheumatism Association 1987 revised criteria for the 
classification of rheumatoid arthritis. Arthritis Rheum 1988;31:31524. 
12. Bolton CF, Sawa GM, Carter K. The effects of temperature on human 
compound action potentials. J NeurolNeurosurg Psychiatry 1981; 44: 
407. 
13.  Lang AH, Puusa A. Dual influence of temperature on com- pound nerve 
action potential. J NeurolSci 1981; 51: 81.  
14.  Johnson EW, Olsen KJ. Clinical value of motor nerve conduc- tion 
velocity determination. JAMA 1960; 172: 2030.  
15. Regan C. The clinical feature of rheumatoid arthritis. JAMA  
16. Weinberger A, Kesler A, Pinkhas J. Fever in various rheumatic diseases. 
ClinRheumatol 1985; 4: 258-66.  
17. Anderson RJ. Polyarticular arthritis. Kelley, W. N. Harris, ED, Ruddy S, 
Sledge CB, eds. Textbook of Rheumatology W.B. Saunders Company 
Philadelphia, London, Toronto; 1981; 393402. 
18. Johnson EW, Olsen KJ. Clinical value of motor nerve conduc- tion 
velocity determination. JAMA 1960; 172: 2030 
19. Beghi E, Monticelli ML. Chronic symmetric symptomatic 
polyneuropathy in the elderly: a field screening investigation of risk 
factors for polyneuropathy in two Italian communities. Italian General 
Practitioner Study Group (IGPST). J ClinEpidemiol 1998;51:697702. 
20. Mold JW, Vesely SK, Keyl BA, Schenk JB, Roberts M. The prevalence, 
predictors, and consequences of peripheral sensory neuropathy in older 
patients. J Am Board FamPract 2004;17:309-18. 
21. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen 
FH, van’t Hof M, et al. The prognostic value of anti-cyclic citrullinated 
peptide antibody in patients with recent-onset rheumatoid arthritis. 
Arthritis Rheum 2000;43:1831-5. 
22. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld 
FC, Zanelli E, et al. Association between HLA class II genes and 
autoantibodies to cyclic citrullinated peptides (CCPs) influences the 
severity of rheumatoid arthritis. Arthritis Rheum 2004;50:211321.  
23. Ceccato F, Roverano S, Barrionuevo A, Rillo O, Paira S. The role of 
anticycliccitrullinated peptide antibodies in the differential diagnosis of 
elderly-onset rheumatoid arthritis and polymyalgia rheumatica. 
ClinRheumatol 2006;25:854-7.  
24. Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, 
Ronnelid J. Rheumatoid factor and antibodies to cyclic citrullinated 
peptides are associated with severe extra-articular manifestations in 
rheumatoid arthritis. Ann Rheum Dis 2007;66:59-64. 
25  Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide 
antibody, smoking, alcohol consumption, and disease duration as risk 
factors for extraarticular manifestations in Korean patients with 
rheumatoid arthritis. J Rheumatol 2008;35:995-1001. 
26. Nadkar MY, Agarwal R, Samant RS, Chhugani SJ, Idgunji SS, Iyer S, et 
al. Neuropathy in rheumatoid arthritis. J Assoc Physicians India 
2001;49:217-20.  
27. Agarwal V, Singh R, Wiclaf, Chauhan S, Tahlan A, Peripheral 
NeuropahtyWithRhuematoid Arthritis 255www.e-arm.org  
28. Ahuja CK, et al. A clinical, electrophysiological, and pathological study 
of neuropathy in rheumatoid arthritis. ClinRheumatol 2008;27:841-4. 
29.  Lanzillo B, Pappone N, Crisci C, di Girolamo C, Massini R, Caruso G. 
Subclinical peripheral nerve involvement in patients with rheumatoid 
arthritis. Arthritis Rheum 1998;41:1196-202.  
30. Fleming A, Dodman S, Crown JM, Corbett M. Extraarticular features in 
early rheumatoid disease. Br Med J 1976;1:1241-3.  
31. Bayrak AO, Durmus D, Durmaz Y, Demir I, Canturk F, Onar MK. 
Electrophysiological assessment of polyneuropathic involvement in 
rheumatoid arthritis: relationships among demographic, clinical and 
laboratory findings. Neurol Res 2010;32:711-4. 
 
  
 
77 
The ideal individual with high risk of developing peripheral 
neuropathy in rheumatoid arthritis patients 
o Age > 40 years 
o Duration of RA greater than 10 years 
o ESR greater than 40 mm/hr 
o Anti-CCF Antibody positive status  
This study is a hypothesis proving study.  
Hence results have high clinical significance. 
                                  
 
PROFORMA 
Name:  
Age:  
Sex:  
Educational status:  
Occupation: 
Address:  
Clinical presentation on admission or OPD: 
Time of onset of symptoms/Duration: 
PAST HISTORY: 
Diabetes  
CKD   
Thyroid diseases  :  
PERSONAL HISTORY : 
                   Alcohol:  
 
 
FAMILY HISTORY:  
Rheumatoid arthritis :  
Diabetes: 
GENERAL EXAMINATION 
Anemia: 
Arthritis { DAS 28 SCORING SYSTEM}:  
Extra articular manifestations:  
VITALS:  - Pulse rate 
              - Blood pressure               
EXAMINATION OF CARDIOVASCULAR SYSTEM:  
EXAMINATION OF RESPIRATORY SYSTEM:   
EXAMINATION OF ABDOMEN:   
EXAMINATION OF CENTRAL NERVOUS SYSTEM:  
- Level of consciousness:  
Peripheral nervous system examination : 
Motor : 
 - Bulk. 
  - Tone.  
  - Power. 
 - Reflexes.  
Sensory : 
  - Touch . 
 - Pain . 
 - Temperature . 
 - Vibration and  joint position sense . 
Autonomic system  
INVESTIGATIONS 
 BLOOD 
TC / DC :  
ESR :  
HB :  
Platelet count :  
Peripheral smear study :  
RBS :  
RFT  :  
CRP:  
RF/Anti -CCP FACTOR:  
LFT  with lipid profile:  
ELISA FOR HIV :   
NERVE  CONDUCTION STUDY :  
- Median nerve . 
- Ulnar nerve . 
- Tibial nerve. 
 -Common peroneal nerve. 
-Sural  nerve 
 
  
 

  
 
 
 
 
 
 
